Micronutrient Supplementation and Bone Health After Prophylactic Total Gastrectomy in Patients With CDH1 Variants.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
18 09 2023
Historique:
received: 28 11 2022
pmc-release: 23 03 2024
medline: 19 9 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: ppublish

Résumé

Patients with germline variants in CDH1 who undergo prophylactic total gastrectomy (TG) are at risk of altered nutrient and drug absorption due to modified gastrointestinal anatomy. Bone mineral density loss and micronutrient deficiencies have not been described previously in this patient population. In this study we included 94 patients with germline CDH1 variants who underwent prophylactic TG between October 2017 and February 2022. We examined pre- and post-gastrectomy bone mineral density (BMD); serum biomarkers including calcium, phosphorus, alkaline phosphatase, and 25 (OH)-vitamin D; and postoperative adherence to calcium and multivitamin supplementation. Almost all patients (92/94, 98%) lost a substantial amount of weight post-TG, with an average weight loss of 26.5% at 12 months post-surgery. Serum biomarkers of mineral metabolism, namely calcium and phosphorus, did not change significantly after TG. However, average BMD was decreased in all patients at 12 months post-TG. Nonadherence to calcium supplementation was associated with a decrease in BMD. Nonadherence to multivitamin supplementation was associated with greater percent BMD loss in the femoral neck and total hip. Appropriate micronutrient supplementation and nutritional counseling pre- and postoperatively in patients undergoing prophylactic TG are important to mitigate the long-term effects of gastrectomy on bone health.

Identifiants

pubmed: 36950857
pii: 7084400
doi: 10.1210/clinem/dgad137
pmc: PMC10505525
doi:

Substances chimiques

Calcium SY7Q814VUP
Vitamins 0
Vitamin D 1406-16-2
Calcium, Dietary 0
Biomarkers 0
Phosphorus 27YLU75U4W
CDH1 protein, human 0
Antigens, CD 0
Cadherins 0

Banques de données

ClinicalTrials.gov
['NCT03030404']

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2635-2642

Subventions

Organisme : NCI NIH HHS
Pays : United States
Organisme : NIDDK NIH HHS
Pays : United States

Informations de copyright

Published by Oxford University Press on behalf of the Endocrine Society 2023.

Références

J Bone Miner Metab. 2018 Jul;36(4):462-469
pubmed: 28766134
J Steroid Biochem Mol Biol. 2017 Oct;173:202-210
pubmed: 28027914
Surg Endosc. 2013 May;27(5):1509-20
pubmed: 23263644
In Vivo. 2021 Jul-Aug;35(4):2369-2377
pubmed: 34182520
BMJ. 1996 May 18;312(7041):1254-9
pubmed: 8634613
Lancet Diabetes Endocrinol. 2014 Feb;2(2):165-74
pubmed: 24622720
Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1505-19
pubmed: 22998066
J Formos Med Assoc. 2021 Jan;120(1 Pt 1):25-33
pubmed: 31859187
Rev Endocr Metab Disord. 2017 Jun;18(2):153-165
pubmed: 28516265
JAMA Oncol. 2019 Sep 01;5(9):1325-1331
pubmed: 31246251
Surg Today. 2022 Feb;52(2):182-188
pubmed: 33630154
Medicine (Baltimore). 2018 Jan;97(1):e9582
pubmed: 29505541
Endocr Pract. 2019 Dec;25(12):1346-1359
pubmed: 31682518
Lancet Oncol. 2020 Aug;21(8):e386-e397
pubmed: 32758476
Osteoporos Int. 2020 Feb;31(2):267-275
pubmed: 31776636
J Med Genet. 2019 Dec;56(12):838-843
pubmed: 31296550

Auteurs

Lauren A Gamble (LA)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Rachael Lopez (R)

Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD 20892, USA.
US Public Health Service, Washington, DC 20245, USA.

Suraj Rajasimhan (S)

Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.

Sarah G Samaranayake (SG)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cassidy Bowden (C)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Amber L Famiglietti (AL)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Andrew M Blakely (AM)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Smita Jha (S)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.

Mark A Ahlman (MA)

Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.

Jeremy L Davis (JL)

Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH